Phase 2 16 items
Studies
- TULIP: the original TA-8995 (obicetrapib) trial cuts LDL-C by up to 45.3% and raises HDL-C by up to 179% with no serious adverse events (Lancet 2015)
- Phase 2 trial in 102 Japanese patients: obicetrapib 10mg on background statin cuts LDL-C by 45.8% and raises HDL-C by 159% (J Atheroscler Thromb 2024)
- Phase 2 trial: obicetrapib plus ezetimibe on top of high-intensity statins cuts LDL-C by 63.4%, with 87% of patients reaching under 55 mg/dL (J Clin Lipidol 2023)
- Phase 2 trial in 120 patients: obicetrapib on top of high-intensity statins cuts LDL-C by up to 51% and raises HDL-C by up to 165% (Nat Med 2022)
- The dal-PLAQUE imaging trial finds no evidence dalcetrapib harms the arterial wall after the failure of torcetrapib (Lancet 2011)
- Twice-daily torcetrapib doubles HDL cholesterol in the first published proof-of-concept trial of a CETP inhibitor (N Engl J Med 2004)
- The first human trial of JTT-705 finds 900 mg raises HDL cholesterol by 34 percent while cutting CETP activity by 37 percent (Circulation 2002)
- Obicetrapib, the rebirth of CETP inhibitors? A review of ROSE and ROSE2 phase 2 data ahead of four ongoing phase 3 trials (Curr Atheroscler Rep 2024)
- Reversing the tide of CETP inhibitor disappointments: a review of obicetrapib and its ROSE2 data ahead of pivotal phase 3 outcomes trials (Curr Atheroscler Rep 2024)
- Adding dalcetrapib to pravastatin reshapes HDL composition and boosts two cholesterol efflux pathways in a phase IIb dose-ranging study (Am Heart J 2012)
- A 48-week trial finds dalcetrapib raises HDL cholesterol by a third with no measurable effect on lymph node size (Eur Heart J 2010)
- Pooled phase II data show dalcetrapib raises HDL cholesterol up to 36 percent without the blood pressure or aldosterone effects seen with torcetrapib (Am J Cardiol 2009)
- Torcetrapib alone raises HDL cholesterol by up to 54.5 percent, with less LDL benefit in patients with high triglycerides (J Am Coll Cardiol 2006)
- Adding torcetrapib to atorvastatin raises HDL cholesterol by up to 40 percent with no dose-related rise in adverse events (J Am Coll Cardiol 2006)
- Adding JTT-705 to pravastatin raises HDL cholesterol by 28 percent after just 4 weeks in a placebo-controlled trial (Am J Cardiol 2005)
- The dal-PLAQUE study is designed to track dalcetrapib effects on carotid plaque burden and inflammation with MRI and PET/CT (Am Heart J 2011)